Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
about
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancerPemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)Perspectives on systems biology applications in diabetic kidney diseaseTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerUtilization of genomic signatures to identify phenotype-specific drugsChemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group StudyProspective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancerDNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cellsEmerging role of pemetrexed in ovarian cancer.Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patientsPractical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.Putting oncology patients at riskERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cellsGenomic signatures individualize therapeutic decisions in non-small-cell lung cancer.Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell linesClinical impact of high-throughput gene expression studies in lung cancer.Molecular therapy for the treatment of hepatocellular carcinoma.An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.Independent validation of a model using cell line chemosensitivity to predict response to therapy.Genomic medicine in non-small cell lung cancer: paving the path to personalized care.New biomarkers for lung cancer.DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.Retraction for Harland et al., "Phospholipid bilayers are viscoelastic".Individualizing cancer therapy.Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.Statistical Contributions to Bioinformatics: Design, Modeling, Structure Learning, and Integration.Cancer trial errors revealed.A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them)
P2860
Q21144332-E469D753-3174-44D2-B431-CDAAC8CC1CC6Q24647905-4053C3A5-AE88-4EEA-B3EB-01E011F8A429Q26823206-8B3F2050-24F6-48A9-9505-9A10BB883D74Q28396304-90D197E0-99B5-4532-AF78-F847E976C6C0Q28476014-8323E4FD-723F-42E1-B2BB-9184290EE916Q30433480-471727D6-D80D-4523-8445-5776C8C43B63Q30433483-249A077E-7408-4570-B236-6014821936D8Q33388988-DD62C39D-A8C8-40DB-8030-18C973D4965BQ33463860-3B13DAEB-10E7-454A-B5E7-9A249B728D24Q33509648-25CEC571-ADAF-4A63-B617-7BB523BDAA3EQ34076586-F99D5A8F-75D0-4478-8BE2-53B0DCD9DD98Q35015611-83C52910-E539-4D65-8640-A746D6986911Q35196367-6C430E40-DB95-4B5E-B9ED-AD7B53C2C5AAQ35604133-D282CC22-3B85-4C8B-8F0F-5B8F3325CAE6Q36327434-F8A96085-931A-4BF6-A8F2-2A058F8C68E8Q36615632-60738BEC-8AC9-4EF2-A32D-CC718591A23AQ36709301-07EF3C9E-4551-4C3C-9A48-6D36E9B1E51AQ36985163-F587AD41-8301-4149-9C7F-F88B69C84ED1Q37004642-089B8B9B-9731-46C0-90DD-065976B4C27AQ37040827-99E5CD8C-41E8-4469-8A35-B0FDCB2BF74FQ37146877-19EC974C-AE2E-4807-8503-4EB72E14B079Q37259813-C3DFCB71-6B13-4C0D-B484-14CADD02CFCCQ37317171-5254F396-8E51-4738-9381-B5515C67F0A1Q37329048-C938833F-E297-47E8-B6C2-959394B9C585Q37360211-8928BA74-1D44-4313-9836-7E2C411F11BAQ37619364-5569573A-C239-47D7-908E-7EFC50D1B589Q37640491-8D3FBA01-6A67-4860-B0B2-835D458579D5Q37806311-8EEEFA3D-EB59-421E-8FC4-4E62BF5DA24CQ38089079-8D48158F-8DBF-4177-9B71-30E4DAB3ECA2Q38097536-36D32D4B-8F0A-4099-8B17-E9E64595764AQ42905388-7488BC66-E30B-4CBC-BB5B-DF2CC1890214Q43005370-9BB9F3C7-E7B8-44CB-B22A-39D225C19286Q46547397-3345B06C-E55D-4B11-9E99-20B77632D617Q47110630-67DC04CC-03A5-420D-991F-F37D71992D55Q48710192-485F32B1-9DF0-4EC5-BAD9-EEF648F65D35Q53420712-AA1634B8-0D27-4C1D-962E-6DE6DA6D44A2Q58642712-D29021B4-AEA9-41CF-AF56-06B86440C1F2
P2860
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@ast
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@en
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@nl
type
label
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@ast
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@en
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@nl
prefLabel
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@ast
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@en
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@nl
P2093
P356
P1476
Pharmacogenomic strategies pro ...... patients with advanced cancer.
@en
P2093
Anil Potti
Bala S Balakumaran
Carey Anders
Chaitanya R Acharya
David Harpole
David S Hsu
Holly K Dressman
Johnathan Lancaster
Joseph R Nevins
Katherine Garman
P304
P356
10.1200/JCO.2007.11.0593
P407
P577
2007-10-01T00:00:00Z